Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Otago Medical School staff profiles

Professor Russell Scott

PositionClinical Professor
DepartmentDepartment of Medicine (Christchurch)
QualificationsBMedSc MB ChB(Otago) PhD(Monash) FRACP

Research

  • Prevention and treatment of type 1 Diabetes Mellitus
  • Adipocyte function and Insulin resistance
  • Lipid disorders and CVD
  • Endothelial function and endocrine regulation
  • Diabetes Epidemiology and health outcomes

Publications

Scott, R., Morgan, J., Zimmer, Z., Lam, R. L. H., O'Neill, E. A., Kaufman, K. D., … Raji, A. (2018). A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes, Obesity & Metabolism. Advance online publication. doi: 10.1111/dom.13473

Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civiera, F., Burgess, L., … Scott, R., … for the RUTHERFORD-2 Investigators. (2015). PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet, 385(9965), 331-340. doi: 10.1016/S0140-6736(14)61399-4

Young, J. M., Molyneux, S. L., Florkowski, C. M., Frampton, C. M., George, P. M., & Scott, R. S. (2012). Pharmacokinetic comparison of a generic coenzyme Q10 solubilizate and a formulation with soybean phytosterols. Phytotherapy Research, 26, 1092-1096. doi: 10.1002/ptr.3667

Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., Nicholls, M. G., Scott, R. S., & George, P. M. (2012). A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. American Journal of Hypertension, 25(2), 261-270. doi: 10.1038/ajh.2011.209

Meininger, G. E., Scott, R., Alba, M., Shentu, Y., Luo, E., Amin, H., … Goldstein, B. J. (2011). Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care, 34(12), 2560-2566. doi: 10.2337/dc11-1200

Journal - Research Article

Scott, R., Morgan, J., Zimmer, Z., Lam, R. L. H., O'Neill, E. A., Kaufman, K. D., … Raji, A. (2018). A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes, Obesity & Metabolism. Advance online publication. doi: 10.1111/dom.13473

Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civiera, F., Burgess, L., … Scott, R., … for the RUTHERFORD-2 Investigators. (2015). PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet, 385(9965), 331-340. doi: 10.1016/S0140-6736(14)61399-4

Young, J. M., Molyneux, S. L., Florkowski, C. M., Frampton, C. M., George, P. M., & Scott, R. S. (2012). Pharmacokinetic comparison of a generic coenzyme Q10 solubilizate and a formulation with soybean phytosterols. Phytotherapy Research, 26, 1092-1096. doi: 10.1002/ptr.3667

Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., Nicholls, M. G., Scott, R. S., & George, P. M. (2012). A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. American Journal of Hypertension, 25(2), 261-270. doi: 10.1038/ajh.2011.209

Meininger, G. E., Scott, R., Alba, M., Shentu, Y., Luo, E., Amin, H., … Goldstein, B. J. (2011). Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care, 34(12), 2560-2566. doi: 10.2337/dc11-1200

King, R. I., Florkowski, C. M., Yeo, J., Walmsley, T. A., Shand, B. I., Scott, R. S., & George, P. M. (2011). What is the best predictor of the atherogenic LDL subclass phenotype ‘pattern B’ in patients with type 2 diabetes mellitus? Annals of Clinical Biochemistry, 48(2), 166-169. doi: 10.1258/acb.2010.010185

Miller, L. J., Willis, J. A., Pearce, J., Barnett, R., Darlow, B. A., & Scott, R. S. (2011). Urban-rural variation in childhood type 1 diabetes incidence in Canterbury, New Zealand, 1980 to 2004. Health & Place, 17(1), 248-256. doi: 10.1016/j.healthplace.2010.10.010

Sorrenson, B., Suetani, R. J., Bickley, V. M., George, P. M., Williams, M. J. A., Scott, R. S., & McCormick, S. P. A. (2011). An ABCA1 truncation shows no dominant negative effect in a familial hypoalphalipoproteinemia pedigree with three ABCA1 mutations. Biochemical & Biophysical Research Communications, 409(3), 400-405. doi: 10.1016/j.bbrc.2011.05.006

Scott, R., Donoghoe, M., Watts, G. F., O'Brien, R., Pardy, C., Taskinen, M.-R., … Manning, P., … Keech, A. C. (2011). Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovascular Diabetology, 10, 102. doi: 10.1186/1475-2840-10-102

Eady, S., Wallace, A., Willis, J., Scott, R., & Frampton, C. (2011). Consumption of a plant sterol-based spread derived from rice bran oil is effective at reducing plasma lipid levels in mildly hypercholesterolaemic individuals. British Journal of Nutrition, 105(12), 1808-1818. doi: 10.1017/S0007114510005519

Callahan, A., Amarenco, P., Goldstein, L. B., Sillesen, H., Messig, M., Samsa, G. P., … Scott, R., … for the SPARCL Investigators. (2011). Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Archives of Neurology, 68(10), 1245-1251. doi: 10.1001/archneurol.2011.146

Maclean, A., McKenney, J. M., Scott, R., Brinton, E., Bays, H. E., Mitchel, Y. B., … Maccubbin, D. L. (2011). Efficacy and safety of extended-release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology, 18(1), 37-45.

Young, J. M., Molyneux, S. L., Reinheimer, A. M., Florkowski, C. M., Frampton, C. M., Scott, R., & George, P. M. (2011). Relationship between plasma coenzyme Q10, asymmetric dimethylarginine and arterial stiffness in patients with phenotypic or genotypic familial hypercholesterolemia on long-term statin therapy. Atherosclerosis, 218(1), 188-193. doi: 10.1016/j.atherosclerosis.2011.04.034

Wallace, A., Eady, S., Miles, M., Martin, H., McLachlan, A., Rodier, M., Willis, J., Scott, R., & Sutherland, J. (2010). Demonstrating the safety of manuka honey UMF® 20+ in a human clinical trial with healthy individuals. British Journal of Nutrition, 103(7), 1023-1028. doi: 10.1017/S0007114509992777

Lewis, J. G., Borowski, K. K., Shand, B. I., George, P. M., & Scott, R. S. (2010). Plasma sex hormone-binding globulin, corticosteroid-binding globulin, cortisol, and free cortisol levels in outpatients attending a lipid disorders clinic: A cross-sectional study of 1137 subjects. Hormone & Metabolic Research, 42(4), 274-279. doi: 10.1055/s-0029-1243260

Lever, M., George, P. M., Slow, S., Elmslie, J. L., Shand, B. I., Scott, R. S., & Chambers, S. T. (2010). Fibrates plus betaine: A winning combination? [Viewpoint]. New Zealand Medical Journal, 123(1324). Retrieved from http://journal.nzma.org.nz/journal/123-1324/4389/content.pdf

King, R. I., Scott, R. S., Florkowski, C. M., Laurie, A. D., Reid, N., & George, P. M. (2010). Homozygous familial hypercholesterolaemia and treatment by LDL apheresis [Clinical correspondence]. New Zealand Medical Journal, 123(1319). Retrieved from http://journal.nzma.org.nz/journal/123-1319/4230/content.pdf

Simes, J., Voysey, M., O'Connell, R., Glasziou, P., Best, J. D., Scott, R., … for the FIELD Study Investigators, including Manning, P. (2010). A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PLoS ONE, 5(1), e8580. doi: 10.1371/journal.pone.0008580

Monro, J. A., Wallace, A., Mishra, S., Eady, S., Willis, J. A., Scott, R. S., & Hedderley, D. (2010). Relative glycaemic impact of customarily consumed portions of eighty-three foods measured by digesting in vitro and adjusting for food mass and apparent glucose disposal. British Journal of Nutrition, 104(3), 407-417. doi: 10.1017/S0007114510000589

Miller, L. J., Pearce, J., Barnett, R., Willis, J., Darlow, B. A., & Scott, R. S. (2009). Is population mixing associated with childhood type 1 diabetes in Canterbury, New Zealand? Social Science & Medicine, 68(4), 625-630. doi: 10.1016/j.socscimed.2008.11.027

Lever, M., George, P. M., Slow, S., Elmslie, J. L., Scott, R. S., Richards, A. M., Fink, J. N., & Chambers, S. T. (2009). Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovascular Drugs & Therapy, 23(5), 395-401. doi: 10.1007/s10557-009-6188-1

Elmslie, J. L., Porter, R. J., Joyce, P. R., Hunt, P. J., Shand, B. I., & Scott, R. S. (2009). Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Australian & New Zealand Journal of Psychiatry, 43(1), 53-60. doi: 10.1080/00048670802534341

Scott, R., O'Brien, R., Fulcher, G., Pardy, C., D'Emden, M., Tse, D., … on behalf of the Fenofibrate Intervention and Event Lowering in Diabete (FIELD) Study Investigators, including Manning, P. (2009). Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care, 32(3), 493-498. doi: 10.2337/dc08-1543

Wallace, A. J., Eady, S. L., Willis, J. A., Scott, R. S., Monro, J. A., & Frampton, C. M. (2009). Variability in measurements of blood glucose response to foods in human subjects is not reduced after a standard breakfast. Nutrition Research, 29(4), 238-243. doi: 10.1016/j.nutres.2009.03.003

Lewis, J. G., Shand, B. I., Frampton, C. M., Elder, P. A., & Scott, R. S. (2009). Plasma levels of sex hormone-binding globulin, corticosteroid-binding globulin and cortisol in overweight subjects who develop impaired fasting glucose: A 3-year prospective study. Hormone & Metabolic Research, 41(3), 255-259. doi: 10.1055/s-0028-1087190

Shand, B. I., Scott, R. S., Lewis, J. G., Elder, P. A., & Frampton, C. M. (2009). Comparison of indices of insulin resistance with metabolic syndrome classifications to predict the development of impaired fasting glucose in overweight and obese subjects: A 3-year prospective study. International Journal of Obesity, 33(11), 1274-1279. doi: 10.1038/ijo.2009.169

Lewis, J. G., Shand, B. I., Elder, P. A., & Scott, R. S. (2008). Plasma retinol-binding protein is unlikely to be a useful marker of insulin resistance. Diabetes Research & Clinical Practice, 80(1), e13-e15.

Scott, R., Loeys, T., Davies, M. J., Engel, S. S., & Sitagliptin Study 801 Group. (2008). Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes, Obesity & Metabolism, 10(10), 959-969.

Wallace, A. J., Eady, S. L., Scott, R. S., Willis, J. A., & Frampton, C. M. (2008). Considerable temporal variability in glucose reference curves in humans for a year period. Nutrition Research, 28(8), 495-500.

Young, J. M., Strey, C. H., George, P. M., Sies, C. W., Florkowski, C. M., Frampton, C. M., & Scott, R. S. (2008). Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure. European Journal of Heart Failure, 10(5), 463-466. doi: 10.1016/j.ejheart.2008.03.010

Lewis, J. G., Shand, B. I., Frampton, C. M., Elder, P. A., & Scott, R. S. (2008). Plasma retinol-binding protein is not a marker of insulin resistance in overweight subjects: A three year longitudinal study. Clinical Biochemistry, 41(13), 1034-1038.

Dawson, S. I., Willis, J., Florkowski, C. M., & Scott, R. S. (2008). All-cause mortality in insulin-treated diabetic patients: A 20-year follow-up. Diabetes Research & Clinical Practice, 80(1), e6-e9.

Chan, J. C., Scott, R., Arjona Ferreira, J. C., Sheng, D., Gonzalez, E., Davies, M. J., … Williams-Herman, D. (2008). Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes, Obesity & Metabolism, 10(7), 545-555.

Dawson, S. I., Willis, J., Florkowski, C. M., & Scott, R. S. (2008). Cause-specific mortality in insulin-treated diabetic patients: A 20-year follow-up. Diabetes Research & Clinical Practice, 80(1), 16-23.

Plant, S., Shand, B., Elder, P., & Scott, R. (2008). Adiponectin attenuates endothelial dysfunction induced by oxidised low-density lipoproteins. Diabetes & Vascular Disease Research, 5(2), 102-108.

Homer, V. M., Marais, A. D., Charlton, F., Laurie, A. D., Hurndell, N., Scott, R., … George, P. M., & Lambert, G. (2008). Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis, 196(2), 659-666.

Shand, B., Scott, R., Connolly, S., Clarke, R., Baker, J., Elder, P., Frampton, C., & Yeo, J. (2007). Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes. Diabetes, Obesity & Metabolism, 9, 540-547.

Scott, R., Wu, M., Sanchez, M., & Stein, P. (2007). Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. International Journal of Clinical Practice, 61(1), 171-180.

Shand, B., Elder, P., Scott, R., Poa, N., & Frampton, C. M. (2007). Comparison of plasma adiponectin levels in New Zealand Māori and Caucasian individuals. New Zealand Medical Journal, 120(1257). Retrieved from http://journal.nzma.org.nz/journal/120-1257/2606/content.pdf

Young, J. M., Shand, B. I., McGregor, P. M., Scott, R. S., & Frampton, C. M. (2006). Comparative effects of enzogenol((R)) and vitamin C supplementation versus vitamin C alone on endothelial function and biochemical markers of oxidative stress and inflammation in chronic smokers. Free Radical Research, 40(1), 85-94.

The DIAMOND Project Group, including Darlow, B., Scott, R., & Willis, J. (2006). Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabetic Medicine, 23, 857-866.

Keech, A., Simes, J., Barter, P., Best, J., Scott, R., Taskinen, M.-R., & on behalf of the FIELD Management Committee. (2006). Correction to the FIELD study report. Lancet, 368, 1415. doi: 10.1016/S0140-6736(06)69594-9

Shand, B., Elder, P., Scott, R., Frampton, C., & Willis, J. (2006). Biovariability of plasma adiponectin. Clinical Chemistry & Laboratory Medicine, 44(10), 1164-1168.

Wallace, A. J., Willis, J. A., Monro, J. A., Frampton, C. M., Hedderley, D. I., & Scott, R. S. (2006). No difference between venous and capillary blood sampling and the Minimed continuous glucose monitoring system for determining the blood glucose response to food. Nutrition Research, 26, 403-408.

Wallace, A. J., Monro, J. A., Hedderley, D. I., Willis, J. A., & Scott, R. S. (2006). Determining the glycemic glucose equivalent value of foods in humans. Nutrition Research, 26, 47-52.

Strey, C. H., Young, J. M., Lainchbury, J. G., Frampton, C. M., Nicholls, M. G., Richards, A. M., & Scott, R. S. (2006). Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart, 92(11), 1603-1609. doi: 10.1136/hrt.2005.082560

Chee, L., Spearing, R. L., Morris, C. M., McDonald, M., Hanrahan, V., Ebbett, A., Scott, R., Florkowski, C., … Patton, W. N. (2005). Acquired myeloma-associated Type III hyperlipidaemia treated by nonmyeloablative HLA-identical sibling allogeneic stem cell transplant using a donor with essential thrombocythaemia (ET): Evidence of engraftment without manifestation of ET in recipient. Bone Marrow Transplantation, 35, 1213-1214.

Lever, M., George, P. M., Dellow, W. J., Scott, R. S., & Chambers, S. T. (2005). Homocysteine, glycine betaine, and N,N-dimethylglycine in patients attending a lipid clinic. Metabolism, 54, 1-14.

Strey, C. H., Young, J. M., Molyneux, S. L., George, P. M., Florkowski, C. M., Scott, R. S., & Frampton, C. M. (2005). Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis, 179(1), 201-206.

Scott, R., Best, J., Forder, P., Taskinen, M.-R., Simes, J., Barter, P., & Keech, A. (2005). Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate. Cardiovascular Diabetology, 4(13). Retrieved from http://www.cardiab.com/content/pdf/1475-2840-4-13.pdf

FIELD Study Investigators, including Scott, R., & Mann, S. (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet, 366(9500), 1849-1861.

Lunt, H., Kendall, D., Moore, M. P., Scott, R. S., Cole, D., Frampton, C. M., & Cullens, M. (2004). Prospective audit of conversion from regular to lispro insulin during routine clinical care. Internal Medicine Journal, 34(3), 320-323.

Lewis, J. G., Shand, B. I., Elder, P. A., & Scott, R. S. (2004). Plasma sex hormone-binding globulin rather than corticosteroid-binding globulin is a marker of insulin resistance in obese adult males. Diabetes, Obesity & Metabolism, 6(4), 259-263.

Laurie, A. D., Scott, R. S., & George, P. M. (2004). Genetic screening of patients with familial hypercholesterolaemia (FH): A New Zealand perspective. Atherosclerosis Supplements, 5(5), 13-15.

Strey, C. H., Young, J., Collier, M., Florkowski, C. M., Shand, B. I., & Scott, R. S. (2004). The postprandial state does not impair endothelial function in women with type 2 diabetes irrespective of glycaemic control. Diabetologia, 47(10), 1838-1846.

Shand, B. I., Scott, R. S., Elder, P. A., & George, P. M. (2003). Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes, Obesity & Metabolism, 5(5), 349-353.

Hall, R. J., Merriman, M. E., Green, R. A., Markham, V. H., Smyth, D. J., Heward, J. M., … Braithwaite, A., … Darlow, B. A., … Harrison, A. A., Highton, J., Hunt, P. J., Manning, P. J., … Scott, R. S., Taylor, B. J., Willis, J., … Merriman, T. R. (2003). The Deleted in Colorectal Carcinoma (DCC) gene 201 R → G polymorphism: No evidence for genetic association with autoimmune disease. European Journal of Human Genetics, 11, 840-844.

Davidson, M. H., Ose, L., Frohlich, J., Scott, R. S., Dujovne, C. A., Escobar, I., … Mercuri, M. (2003). Differential effects of simvastation and atorvastation on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. Clinical Cardiology, 26(11), 509-514.

Shand, B., Strey, C. H., Scott, R. S., Morrison, Z., & Gieseg, S. P. (2003). Pilot study on the clinical effects of dietary supplementation with Enzogenol®, a flavonoid extract of pine bark and vitamin C. Phytotherapy Research, 17(5), 490-494. doi: 10.1002/ptr.1181

Phillips, P., Karrasch, J., Scott, R. S., Wilson, D., & Moses, R. (2003). Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care, 26(2), 269-273.

Florkowski, C. M., Scott, R. S., Graham, P. J., Han, D. Y., & Moir, C. L. (2003). Cause-specific and total mortality in the Canterbury (New Zealand) insulin-treated Diabetic Registry population: a 15-year follow-up study. Diabetic Medicine, 20(3), 191-197.

Willis, J., Scott, R. S., Darlow, B. A., Nesbit, J., Anderson, P., Moore, M. P., Lunt, H., & Cole, D. R. (2002). Incidence of type 1 diabetes mellitus diagnosed before age 20 years in Canterbury, New Zealand over the last 30 years. Journal of Pediatric Endocrinology & Metabolism, 15, 637-643.

de Jongh, S., Ose, L., Szamosi, T., Gagné, C., Lambert, M., Scott, R. S., … Kastelein, J. J. P. (2002). For the Simvastatin in Children Study Group. Efficacy and safety of statin therapy in children with Familial Hypercholesterolaemia. Circulation, 106, 2231-2237.

Willis, J., Scott, R. S., Darlow, B. A., Lewy, H., Ashkenazi, I., & Laron, Z. (2002). Seasonality of birth and onset of clinical disease in children and adolescents (0 - 19 years) with Type 1 Diabetes Mellitus in Canterbury, New Zealand. Journal of Pediatric Endocrinology & Metabolism, 15(5), 645-647.

Scott, R. S. (2002). Stroke and heart disease prevention through lipid management. Hong Kong Practitioner, 24, 1-4.

Bunn, C., Lintott, C. J., Scott, R. S., & George, P. M. (2002). Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort. Human Mutation, 19(3), 311.

Crossen, K., Scott, R. S., McGeoch, G. R. B., & George, P. M. (2001). Implementation of evidence based cardiovascular risk treatments by general practitioners. New Zealand Medical Journal, 114, 260-262.

Collier, M., Shand, B. I., Scott, R. S., & Walmsley, T. A. (2001). The effect of magnesium supplementation on cardiovascular risk factors in people with type 2 diabetes. Journal New Zealand Dietetic Association, 55, 52-57.

Florkowski, C. M., Scott, R. S., Coope, P. A., Graham, P. J., & Moir, C. L. (2001). Age at diagnosis, glycaemic control and the development of retinopathy in a population-based cohort of type 1 diabetic subjects in Canterbury, New Zealand. Diabetes Research & Clinical Practice, 52, 125-131.

Florkowski, C. M., Scott, R. S., Coope, P. A., & Moir, C. L. (2001). Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study. Diabetes Research & Clinical Practice, 52, 113-120.

Brown, L. J., Scott, R. S., & Moir, C. L. (2001). All-cause mortality in the Canterbury (New Zealand) insulin-treated diabetic registry population. Diabetes Care, 24, 56-63.

Shand, B. I., Scott, R. S., Florkowski, C. M., Reynolds, M., & Ikram, H. (2001). A comparison of post-prandial changes in flow-mediated dilatation in patients with type 2 diabetes with and without macroalbuminuria. Diabetes Nutrition & Metabolism, 14, 201-206.

Ose, L., Davidson, M. H., Stein, E. A., Kastelein, J. J. P., Scott, R. S., Junninghake, D., … Mitchel, Y. B. (2000). Lipid altering efficacy and safety of simvastatin 80 mg/day: Longterm experience in a large group of patients with hypercholesterolaemia. Clinical Cardiology, 23, 39-46.

Thiart, R., Varret, M., Lintott, C. J., Scott, R. S., Loubser, O., du Plessis, L., … Kotze, M. J. (2000). Mutation analysis in a small cohort of New Zealand patients originating from the United Kingdom demonstrates genetic heterogeneity in familial hypercholesterolaemia. Molecular & Cellular Probes, 14, 299-304.

Florkowski, C. M., & Scott, R. S. (1999). Type 2 diabetes towards the new millenium - the relative importance of glycaemic versus lipid control. Australian & New Zealand Journal of Medicine, 29, 249.

Florkowski, C. M., George, P. M., Willis, J., Stott, M. K., Burt, M. J., Upton, J. D., … Scott, R. S. (1999). Haemochromatosis gene mutations Cys282Tyr and His63Asp are not increased in type 2 diabetic patients compared with the Canterbury (New Zealand) general population. Diabetes Research & Clinical Practice, 43, 199-203.

Nesbit, J. W., Willis, J. A., Scott, R. S., & Darlow, B. A. (1999). Susceptibility alleles for type 1 diabetes in childhood and adolescent diabetes cases and insulin deficient adult-onset diabetic subjects. Australian & New Zealand Journal of Medicine, 29, 597.

Ose, L., Kastelein, J. J. P., Scott, R. S., Stein, E. A., Campodonico, S., Escobar, J. D., … Mercuri, M. (1998). Efficacy and six-month safety of simvastatin 80mg/day: Results from the Worldwide Simvastin Expanded Dose Program (WSEDP). Nutrition, Metabolism & Cardiovascular Diseases, 8, 143-151.

Willis, J. A., Scott, R. S., Brown, L., Zimmet, P., MacKay, I., & Rowley, M. (1998). Type 1 diabetes in insulin-treated adult-onset diabetic subjects. Diabetes Research & Clinical Practice, 42, 49-53.

Florkowski, C. M., Scott, R. S., Moir, C. L., & Graham, P. J. (1998). Clinical and biochemical outcomes of type 2 diabetes mellitus in Canterbury, New Zealand: a 6-year cohort study. Diabetes Research & Clinical Practice, 40(3), 167-173.

Florkowski, C. M., Scott, R. S., Moir, C. L., & Graham, P. J. (1998). Lipid but not glycaemic parameters predict total mortality from type 2 diabetes mellitus in Canterbury, New Zealand. Diabetic Medicine, 15(5), 386-392.

Payne, C., & Scott, R. S. (1998). Hospital discharges for diabetic foot disease in New Zealand: 1980 - 1993. Diabetes Research & Clinical Practice, 39, 69-74.

Florkowski, C. M., & Scott, R. S. (1998). Outcomes of type 2 diabetes. Diabetes Reviews International, 7, 6-8.

Simons, L. A., & Scott, R. S. (1998). Comparison of Atorvaststin alone versus Simvastatin + cholestyramine in the management of severe primary hypercholesterolaemia (The Six Cities Study). Australian & New Zealand Journal of Medicine, 28, 327-332.

Mann, J., & Scott, R. S. (1998). Lipid-modifying drugs. New Zealand Medical Journal, 111, 285-287.

Willis, J., Scott, R. S., Darlow, B. A., Lunt, H., & Moore, P. (1997). Hepatitis B immunisation and the epidemiology of IDDM in children and adolescents aged <20 years in Canterbury, New Zealand. Diabetes, 46(Suppl. 1), 140A.

Florkowski, C. M., Scott, R. S., Hart, J. B., Willis, J. A., & Campbell, A. (1997). The effect of gliclazide on insulin and proinsulin responses to mixed meal testing in non-insulin dependent diabetes subjects. Nutrition, Metabolism & Cardiovascular Diseases, 7(4), 331-335.

Willis, J. A., Scott, R. S., Brown, L. J., Forbes, L. V., Schmidli, R. S., Zimmet, P. Z., … Rowley, M. J. (1996). Islet cell antibodies and antibodies against glutamic acid decarboxylase in newly diagnosed adult-onset diabetes mellitus. Diabetes Research & Clinical Practice, 33(2), 89-97. doi: 10.1016/0168-8227(96)01281-8

Forbes, L. V., Scott, R. S., Brown, L. J., & Darlow, B. A. (1995). Immunogenetic, clinical and demographic characterization of childhood type 1 diabetes in New Zealand. Diabetes Care, 18(11), 1428-1433.

Schmidli, R. S., Hagan, C., Scott, R. S., Livesey, J., & Forbes, L. V. (1993). Plasma proinsulin in recently diagnosed type 2 diabetes mellitus. Diabetes Research & Clinical Practice, 20(2), 133-138. doi: 10.1016/0168-8227(93)90007-R

Scott, R. S., Brown, L. J., Darlow, B. A., Forbes, L. V., & Moore, M. P. (1992). Temporal variation in incidence of IDDM in Canterbury, New Zealand. Diabetes Care, 15(7), 895-899. doi: 10.2337/diacare.15.7.895

^ Top of page

Journal - Research Other

Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., George, P. M., & Scott, R. S. (2007). Effect of coenzyme Q10 supplementation on simvastatin-induced myalgia. American Journal of Cardiology, 100, 1400-1403. doi: 10.1016/j.amjcard.2007.06.030

Willis, J., Raizis, A., Darlow, B., Scott, R., & Beaven, D. (2006). Type 1 diabetes: Research hopes and their New Zealand implications [Letter]. New Zealand Medical Journal, 119(1228). Retrieved from http://journal.nzma.org.nz/journal/119-1228/1819/content.pdf

Willis, J. A., Scott, R. S., & Darlow, B. A. (2005). -to: Campbell-Stokes PL, Taylor BJ on behalf of the New Zealand Children's Diabetes Working Group (2005) Prospective incidence study of diabetes mellitus in New Zealand children aged 0 to 14 years. Diabetologia 48: 643-648. Diabetologia, 48(11), 2442-2443.

More publications...